The majority of gastroenteropancreatic well-differentiated endocrine carcinomas (WDEC) express somatostatin receptors (SSTR). To correlate the expression of SSTR subtypes by reverse transcriptase-polymerase chain reaction (RT-PCR) with clinicopathological features and survival in a group of WDEC patients, 42 WDEC tissue specimens from 33 patients were analysed. All patients were treated with somatostatin analogues and had a median follow-up period of 45 months (range 6–196). Neither SSTR2 and SSTR5 expression nor Ki-67 level alone correlated with survival. A significantly better survival rate was observed in patients with tumours expressing SSTR2, SSTR5 and Ki-67 <2%, compared to those with SSTR2– and SSTR5–negative tumours and Ki-67 ≥2% (p < 0.038), with 5-year survival rates of 91 vs. 43%, respectively. Expression of SSTR2 and SSTR5 appears to play a positive prognostic role, possibly correlated with the high affinity that the available somatostatin analogues display for these 2 specific SSTR subtypes.

Somatostatin receptor subtypes 2 and 5 are associated with better survival in well-differentiated endocrine carcinomas / Corleto, Vito Domenico; Falconi, M; Panzuto, F; Milione, M; DE LUCA, O; Perri, P; Cannizzaro, R; Bordi, C; Pederzoli, P; Scarpa, A; DELLE FAVE, Gianfranco. - In: NEUROENDOCRINOLOGY. - ISSN 0028-3835. - STAMPA. - (2009), pp. 223-230. [10.1159/000167796]

Somatostatin receptor subtypes 2 and 5 are associated with better survival in well-differentiated endocrine carcinomas

CORLETO, Vito Domenico;PANZUTO F;DELLE FAVE, Gianfranco
2009

Abstract

The majority of gastroenteropancreatic well-differentiated endocrine carcinomas (WDEC) express somatostatin receptors (SSTR). To correlate the expression of SSTR subtypes by reverse transcriptase-polymerase chain reaction (RT-PCR) with clinicopathological features and survival in a group of WDEC patients, 42 WDEC tissue specimens from 33 patients were analysed. All patients were treated with somatostatin analogues and had a median follow-up period of 45 months (range 6–196). Neither SSTR2 and SSTR5 expression nor Ki-67 level alone correlated with survival. A significantly better survival rate was observed in patients with tumours expressing SSTR2, SSTR5 and Ki-67 <2%, compared to those with SSTR2– and SSTR5–negative tumours and Ki-67 ≥2% (p < 0.038), with 5-year survival rates of 91 vs. 43%, respectively. Expression of SSTR2 and SSTR5 appears to play a positive prognostic role, possibly correlated with the high affinity that the available somatostatin analogues display for these 2 specific SSTR subtypes.
2009
somatostatin receptor; well-differentiated tumours; somatostatin analogues; survival rate
01 Pubblicazione su rivista::01a Articolo in rivista
Somatostatin receptor subtypes 2 and 5 are associated with better survival in well-differentiated endocrine carcinomas / Corleto, Vito Domenico; Falconi, M; Panzuto, F; Milione, M; DE LUCA, O; Perri, P; Cannizzaro, R; Bordi, C; Pederzoli, P; Scarpa, A; DELLE FAVE, Gianfranco. - In: NEUROENDOCRINOLOGY. - ISSN 0028-3835. - STAMPA. - (2009), pp. 223-230. [10.1159/000167796]
File allegati a questo prodotto
File Dimensione Formato  
Corleto_Somatostatin_2008.pdf

solo gestori archivio

Note: articolo in rivista
Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 394.13 kB
Formato Adobe PDF
394.13 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/229801
Citazioni
  • ???jsp.display-item.citation.pmc??? 17
  • Scopus 52
  • ???jsp.display-item.citation.isi??? 45
social impact